0XOD Stock Chart & Stats
$41.04
-$0.69(-1.68%)
At close: 4:00 PM EDT
$41.04
-$0.69(-1.68%)
Day’s Range― - ―
52-Week Range$16.19 - $51.11
Previous CloseN/A
Volume273.00
Average Volume (3M)519.00
Market Cap
$1.60B
Enterprise Value$1.94B
Total Cash (Recent Filing)$107.97M
Total Debt (Recent Filing)$196.13M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Nov 04, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding48,880,566
10 Day Avg. Volume405
30 Day Avg. Volume519
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue10.28
Enterprise Value/Gross Profit11.32
Enterprise Value/Ebitda-27.68
Forecast
1Y Price Target
$60.20Price Target Upside46.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.22
Revenue Forecast (FY)$320.52M
Bulls Say, Bears Say
Bulls Say
ZUSDURI Commercial GrowthThe launch is converting into substantial commercial scale, with revenue nearly tripling year over year and ZUSDURI growing rapidly. Expanding hospital and community adoption, repeat utilization, and physician confidence can support a broader recurring revenue base over the next several quarters.
Durable Clinical PerformanceLong-term disease-free outcomes and an unreached median response duration support the potential durability of the company’s therapeutic approach. Durable efficacy can strengthen physician confidence, improve differentiation in uro-oncology, and support sustained adoption beyond initial launch activity.
Pipeline And Regulatory ProgressFDA acceptance moves UGN-103 into a formal review process and creates a defined regulatory milestone for a potential additional product. Expansion beyond the current commercial base could diversify revenue, extend the platform’s reach, and improve long-term growth prospects.
Bears Say
Persistent Cash BurnMaterially negative operating and free cash flow shows that the business continues to consume substantial capital despite commercial growth. Continued cash burn can constrain investment flexibility, increase reliance on external funding, and delay the point at which growth translates into self-sustaining operations.
Balance-sheet PressureNegative shareholder equity combined with rising debt indicates limited balance-sheet flexibility while losses continue. Higher leverage can increase financing costs and reduce the company’s ability to absorb execution setbacks, fund pipeline programs, or support commercialization without additional capital.
Execution And Adoption RiskThe gap between activated sites and unique prescribers indicates that commercial access has not yet fully converted into prescribing activity. Slow adoption and conversion may make revenue growth uneven, increase the cost of commercialization, and complicate forecasting as the launch matures.
Urogen Pharma News
0XOD FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest share price was $16.19 and its highest was $51.11 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $1.60B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Nov 04, 2026 which is in 3 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Aug 05, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.265 by -$0.015.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is 0.11.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,880,566 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.265. Following the earnings report the stock price went up 15.824%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in GB:0XOD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.20 (46.69% Upside)
$60.20 (46.69% Upside)
Blogger Sentiment
Bullish
GB:0XOD Sentiment 89%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.83%
12-Months-Change
Fundamentals
Return on Equity
81.78%
Trailing 12-Months
Asset Growth
21.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
0XOD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong positive momentum driven by the ZUSDURI launch (Q2 ZUSDURI revenue of $50.4M, rapid growth in activated accounts and prescribers, durable Phase III durability data, pipeline progress, favorable IP outcomes and materially higher total revenue). Management acknowledged measured near-term risks including continued operating expense increases, quarter-to-quarter variability, remaining net loss (though substantially improved), and early-stage adoption dynamics. They reinforced confidence in cash sufficiency to reach profitability while accelerating investments to support long-term growth.View all GB:0XOD earnings summaries0XOD Stock 12 Month Forecast
Average Price Target
$60.20
▲(46.69% Upside)